A rare coexistence: tyrosinemia type III and Wolff–Parkinson–White syndrome
-
,
Abstract
Objectives
Tyrosinemia type III is an extremely rare autosomal recessive disorder of tyrosine metabolism caused by mutations in the HPD gene, which encodes 4-hydroxyphenylpyruvate dioxygenase (HPPD). Wolff–Parkinson–White (WPW) syndrome is a congenital cardiac conduction disorder characterized by the presence of an accessory atrioventricular pathway. While each condition is rare in isolation, their coexistence has not been previously reported.
Case presentation
We present a unique case of a 6-year-old boy with known WPW syndrome who was admitted with ketotic hypoglycemia after prolonged fasting and omission of propranolol doses. Metabolic work-up revealed persistently elevated plasma tyrosine levels. Genetic testing confirmed tyrosinemia type III due to a novel homozygous HPD variant [c.559A>G (p.Asn187Asp)]. The persistence of the WPW pattern despite decreased plasma tyrosine levels suggests that there is no direct causal relationship. He was also diagnosed with attention-deficit/hyperactivity disorder, specific learning disorder, and borderline intellectual functioning.
Conclusions
This case highlights the importance of metabolic evaluation in pediatric patients presenting with unexplained hypoglycemia, particularly in the presence of pre-existing cardiac disorders.
-
Research ethics: Not appliciable.
-
Informed consent: Informed consent was obtained from the parents.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Use of Large Language Models, AI and Machine Learning Tools: None declared.
-
Conflict of interest: The authors state no conflict of interest.
-
Research funding: None declared.
-
Data availability: Not applicable.
References
1. Ruetschi, U, Cerone, R, Perez-Cerda, C, Schiaffino, MC, Standing, S, Ugarte, M, et al.. Mutations in the 4-hydroxyphenylpyruvate dioxygenase gene (HPD) in patients with tyrosinemia type III. Hum Genet 2000;106:654–62. https://doi.org/10.1007/s004390000307.Suche in Google Scholar PubMed
2. Giardini, O, Cantani, A, Kennaway, NG, D’Eufemia, P. Chronic tyrosinemia associated with 4-hydroxyphenylpyruvate dioxygenase deficiency with acute intermittent ataxia and without visceral and bone involvement. Pediatr Res 1983;17:25–9. https://doi.org/10.1203/00006450-198301000-00005.Suche in Google Scholar PubMed
3. Endo, F, Kitano, A, Uehara, I, Nagata, N, Matsuda, I, Shinka, T, et al.. 4-Hydroxyphenylpyruvic acid oxidase deficiency with normal fumarylacetoacetase: a new variant form of hereditary hypertyrosinemia. Pediatr Res 1983;17:92–6. https://doi.org/10.1203/00006450-198302000-00002.Suche in Google Scholar PubMed
4. Barroso, F, Correia, J, Bandeira, A, Carmona, C, Vilarinho, L, Almeida, M, et al.. Tyrosinemia type III: a case report of siblings and literature review. Rev Paul Pediatr 2020;38:e2018158. https://doi.org/10.1590/1984-0462/2020/38/2018158.Suche in Google Scholar PubMed PubMed Central
5. Chhabra, L, Goyal, A, Benham, MD. Wolff-parkinson-white syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.Suche in Google Scholar
6. Morimoto, A, Ozeki, M, Sasaki, S, Baba, N, Kuwano, Y, Kaneko, T, et al.. Severe hypoglycemia in propranolol treatment for infantile hemangiomas. Pediatr Int 2022;64:e15278. https://doi.org/10.1111/ped.15278.Suche in Google Scholar PubMed PubMed Central
7. Carnovale, C, Gringeri, M, Battini, V, Mosini, G, Invernizzi, E, Mazhar, F, et al.. Beta-blocker-associated hypoglycaemia: new insights from a real-world pharmacovigilance study. Br J Clin Pharmacol 2021;87:3320–31. https://doi.org/10.1111/bcp.14754.Suche in Google Scholar PubMed
8. Thimm, E, Herebian, D, Assmann, B, Klee, D, Mayatepek, E, Spiekerkoetter, U, et al.. Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I. Mol Genet Metab 2011;102:122–5. https://doi.org/10.1016/j.ymgme.2010.11.003.Suche in Google Scholar PubMed
9. D’Eufemia, P, Finocchiaro, R, Celli, M, Raccio, I, Properzi, E, Zicari, A, et al.. Increased nitric oxide release by neutrophils of a patient with tyrosinemia type III. Biomed Pharmacother 2009;63:359–61. https://doi.org/10.1016/j.biopha.2008.06.030.Suche in Google Scholar PubMed
10. de Andrade, RB, Gemelli, T, Rojas, DB, Funchal, C, Dutra-Filho, CS, Wannmacher, CM, et al.. Tyrosine impairs enzymes of energy metabolism in cerebral cortex of rats. Mol Cell Biochem 2012;364:253–61. https://doi.org/10.1007/s11010-012-1225-y.Suche in Google Scholar PubMed
11. Antonini, R, Scaini, G, Michels, M, Matias, MB, Schuck, PF, Ferreira, G, et al.. Effects of omega-3 fatty acids supplementation on inflammatory parameters after chronic administration of L-tyrosine. Metab Brain Dis 2020;35:295–303. https://doi.org/10.1007/s11011-019-00525-x.Suche in Google Scholar PubMed
12. Sgaravatti, AM, Vargas, BA, Zandona, BR, Deckmann, KB, Rockenbach, FJ, Moraes, TB, et al.. Tyrosine promotes oxidative stress in cerebral cortex of young rats. Int J Dev Neurosci 2008;26:551–9. https://doi.org/10.1016/j.ijdevneu.2008.05.007.Suche in Google Scholar PubMed
13. Szymanska, E, Sredzinska, M, Ciara, E, Piekutowska-Abramczuk, D, Ploski, R, Rokicki, D, et al.. Tyrosinemia type III in an asymptomatic girl. Mol Genet Metab Rep 2015;5:48–50. https://doi.org/10.1016/j.ymgmr.2015.10.004.Suche in Google Scholar PubMed PubMed Central
14. Basan, H, Ceylaner, S, Küçükcongar Yavaş, A. Different clinic, different diagnosis: tyrosinemia type 3. Mol Syndromol 2025. https://doi.org/10.1159/000547808 [Epub ahead of print].Suche in Google Scholar PubMed PubMed Central
15. Cerone, R, Holme, E, Schiaffino, MC, Caruso, U, Maritano, L, Romano, C. Tyrosinemia type III: diagnosis and ten-year follow-up. Acta Paediatr 1997;86:1013–5. https://doi.org/10.1111/j.1651-2227.1997.tb15192.x.Suche in Google Scholar PubMed
© 2026 Walter de Gruyter GmbH, Berlin/Boston
